Amneal and metsera announce strategic collaboration to develop and supply portfolio of next-generation medicines for obesity and metabolic diseases

Bridgewater, n.j. & new york--(business wire)--amneal pharmaceuticals, inc. (nasdaq: amrx) (“amneal” or the “company”), a global pharmaceutical company, and metsera, inc. (“metsera”), a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, today announced that they have entered into a collaboration agreement to enable the efficient development and large-scale supply of a portfolio of new weight loss medicines globally. the col.
AMRX Ratings Summary
AMRX Quant Ranking